NasdaqGS:AZTALife Sciences
Can Azenta’s (AZTA) Genomics Partnership Reframe Its Long-Term Growth Story?
Azenta, Inc. reported its third quarter fiscal 2025 results, showing revenue of US$143.94 million and a net loss of US$52.81 million, alongside a reaffirmed guidance for 3% to 5% organic revenue growth for the year.
Additionally, Azenta announced a new collaboration with Frenova and Nephronomics to provide genomic sequencing for a major genomics research program focused on cardio-kidney-metabolic diseases.
We’ll now explore how Azenta’s reaffirmed growth outlook could influence its...